Expression profile of miRNAs in urine samples of bladder cancer patients-Reference-Cited by-同舟云学术

Expression profile of miRNAs in urine samples of bladder cancer patients

Published:2018-12 Issue:12 Volume:12 Page:1311-1321
ISSN:1752-0363
Container-title:Biomarkers in Medicine
language:en
Short-container-title:Biomarkers in Medicine

Author:

Nekoohesh Leila¹,Modarressi Mohammad Hossein²,Mowla Seyed Javad³,Sadroddiny Esmaeil¹,Etemadian Masoud⁴,Afsharpad Mandana⁵,Zolfaghari Faezeh⁶,Barzegari Manijeh⁶,Saffari Mojtaba⁶,Oskooei Vahid Kholghi⁶,Motevaseli Elahe²,Ghafouri-Fard Soudeh⁷

Affiliation:

1. Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

2. Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

3. Faculty of Biological Sciences, Department of Genetics, Tarbiat Modares University, Tehran, Iran

4. Department of Urology, Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, Iran

5. Cancer Control Research Center, Cancer Control Foundation, Iran University of Medical Sciences, Tehran, Iran

6. Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

7. Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Aim: miRNAs have been suggested as biomarkers for bladder cancer. We aimed to find a diagnostic panel of miRNAs based on differential expression of miRNAs in urine specimens of patient with bladder cancer compared with control group. Methods: miR-141, miR-10b, miR-34b and miR-103 were selected to assess their expression in urine samples of 66 bladder cancer patients and 53 matched controls using quantitative real time PCR. Results: miR-10b and miR-34b were upregulated in cases compared with controls. The combination of four miRNAs showed a sensitivity of 75% and specificity of 63.5% with a diagnostic power of 72%. Conclusion: Certain miRNAs can be used as biomarkers for early diagnosis of bladder cancer.

Publisher

Future Medicine Ltd

Subject

Biochemistry (medical),Clinical Biochemistry,Drug Discovery

Link

https://www.futuremedicine.com/doi/pdf/10.2217/bmm-2018-0190

Reference44 articles.

1. EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016

2. Cancer statistics, 2017

3. Economic Burden of Bladder Cancer Across the European Union

4. Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of microRNAs in tumor progression among Iranian population: An overview;Human Gene;2022-12

2. Diagnostic performance of urine and blood microRNAs for bladder cancer: a meta-analysis;Expert Review of Anticancer Therapy;2022-11-18

3. Urinary miRNAs as a Diagnostic Tool for Bladder Cancer: A Systematic Review;Biomedicines;2022-10-31

4. The Role of MicroRNA in the Metastatic Phenotype of Bladder Cancer;Urologic Cancers;2022-09-12

5. The miR-200 Family of microRNAs: Fine Tuners of Epithelial-Mesenchymal Transition and Circulating Cancer Biomarkers;Cancers;2021-11-23